title: Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy.
abstract: Varicella infections pose serious challenges for organ transplant recipients. To determine the safety and immunogenicity of the OMVV and determine the maintenance of OMVV responses in transplanted subjects at varying periods of immunosuppression within the first two yr following transplantation. Eligible subjects given a two-dose OMVV pretransplantation were monitored for AE. Antibody levels were assessed at baseline, six wk post-OMVV, pretransplantation and up to 24 months post-transplantation. Seroprotection was defined as >or=5 gpEU. Twenty-one seronegative children were vaccinated. Following 42 doses, no vaccine-related serious AE occurred. Mab_titer were 17.8 (5.7-910.2) and 183.5 EU (18.8-8116.4) at six and 12 wk, respectively (p < 0.0001). Fourteen (66.7%) participants were transplanted at a median of 16 months (1.5-56) following OMVV and had Mab_titer of 27.2 EU (9.0-236.2) just prior to transplantation. Of 11 who had post-transplantation serology, seroprotection was sustained at three, six and 12 months post-transplantation in 10/11, 12/12 and 8/10 subjects. In five of six subjects with two-yr follow-up, antibody levels remained seroprotective. No breakthrough varicella infections occurred. The receipt of OMVV prior to transplantation induced humoral responses which persisted in the early months following transplantation and up to two yr post-transplantation and was not associated with any serious adverse consequences.
authors.affiliation: Department of Pediatrics, Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
authors.forename: Michelle
authors.initials: M
authors.lastname: Barton
authors.forename: Samia
authors.initials: S
authors.lastname: Wasfy
authors.forename: Toni
authors.initials: T
authors.lastname: Melbourne
authors.forename: Diane
authors.initials: D
authors.lastname: Hébert
authors.forename: Dorothy
authors.initials: D
authors.lastname: Moore
authors.forename: Joan
authors.initials: J
authors.lastname: Robinson
authors.forename: Rocio D
authors.initials: RD
authors.lastname: Marchese
authors.forename: Upton D
authors.initials: UD
authors.lastname: Allen
mesh_terms: D000293:Adolescent; D002644:Chickenpox / Q000276:immunology / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D056724:Immunity, Humoral; D007165:Immunosuppression Therapy / Q000379:methods; D007223:Infant; D018655:Lymphocyte Count; D008297:Male; D016377:Organ Transplantation; D018709:Statistics, Nonparametric; D014181:Transplantation Immunology
chemical_list: D019433:Chickenpox Vaccine